Dr. Buza is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
20 York St
T-209
New Haven, CT 06510Phone+1 203-688-2259Fax+1 203-688-5599
Education & Training
Yale-New Haven Medical CenterResidency, Pathology-Anatomic and Clinical, 2006 - 2009
University of Pécs Medical SchoolClass of 1999
Certifications & Licensure
CT State Medical License 2008 - 2025- American Board of Pathology Pathology - Anatomic
Publications & Presentations
PubMed
- Diandric triploid partial mole versus digynic nonmolar triploidy: is morphological assessment sufficient for the diagnostic distinction?Agnes Nagy, Na Niu, Tong Sun, Natalia Buza, Pei Hui
Histopathology. 2024-12-01 - Utility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas.Michelle Greenman, Stefania Bellone, Tobias Hartwich, Natalia Buza, Alessandro D Santin
Gynecologic Oncology Reports. 2024-12-01 - Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovaria...Levent Mutlu, Blair McNamara, Stefania Bellone, Diego D Manavella, Cem Demirkiran
Clinical & Experimental Metastasis. 2024-10-01
Journal Articles
- Phase II Evaluation of Nivolumab in the Treatment of Persistent or Recurrent Cervical Cancer (NCT02257528/NRG-GY002)Alessandro D Santin, Michael Frumovitz, Natalia Buza, Samir Khleif, Elena S Ratner, Roisin E O'Cearbhaill, Michael Birrer, Gynecologic Oncology
- Minimal Microsatellite Shift in Microsatellite Instability High Endometrial Cancer: A Significant Pitfall in Diagnostic InterpretationXinyu Wu, Douglas Rottmann, Olivia Snir, Pei Hui, Natalia Buza, Nature
Press Mentions
- Reproducibility of Scoring Criteria for HER2 Immunohistochemistry in Endometrial Serous Carcinoma: A Multi-Institutional Interobserver Agreement StudyFebruary 3rd, 2021
Study Validates Combination Therapy for Aggressive Endometrial CancerJune 26th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
